Your browser doesn't support javascript.
loading
The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.
Golkaram, Mahdi; Zhao, Chen; Kruglyak, Kristina; Zhang, Shile; Bilke, Sven.
Affiliation
  • Golkaram M; Illumina, Inc., San Diego, CA, United States of America.
  • Zhao C; Illumina, Inc., San Diego, CA, United States of America.
  • Kruglyak K; Illumina, Inc., San Diego, CA, United States of America.
  • Zhang S; Illumina, Inc., San Diego, CA, United States of America.
  • Bilke S; Illumina, Inc., San Diego, CA, United States of America.
PLoS Comput Biol ; 16(11): e1008332, 2020 11.
Article in En | MEDLINE | ID: mdl-33166276
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Patient Selection / Immunotherapy / Mutation / Neoplasms Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: PLoS Comput Biol Journal subject: BIOLOGIA / INFORMATICA MEDICA Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Patient Selection / Immunotherapy / Mutation / Neoplasms Type of study: Prognostic_studies Limits: Female / Humans / Male Language: En Journal: PLoS Comput Biol Journal subject: BIOLOGIA / INFORMATICA MEDICA Year: 2020 Document type: Article Affiliation country: Country of publication: